表纸
市场调查报告书
商品编码
271821

甲氧西林敏锐度黄色葡萄球菌 (MSSA) 感染疾病:开发中产品分析

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 67 Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

甲氧西林敏感金黄色葡萄球菌 (MSSA) ,是对多数抗生素有抗性的细菌。MSSA通常感染皮肤,不过,也有可能引起肺炎与其他严重的感染疾病。症状有蜂窝性组织炎、伴随疼痛的皮疹、恶心呕吐、发热、肌肉疼痛、腹泻和腹痛等,发病要素是免疫系统低落,烧烫伤,手术的创伤等。

本报告提供甲氧西林敏锐度黄色葡萄球菌 (MSSA) 感染疾病的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等相关的系统性资讯。

简介

  • 调查范围

甲氧西林敏锐度黄色葡萄球菌 (MSSA) 感染疾病概要

治疗药的开发

  • 开发中产品的概要
  • 各企业的开发平台
  • 大学/研究机关所开发的开发平台
  • 企业开发中的产品
  • 大学/研究机关开发中的产品

治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • Antibiotx ApS
  • ContraFect Corp
  • Debiopharm International SA
  • Sealife PHARMA GMBH

药物简介

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 主要消息和新闻稿

附录

目录
Product Code: GMDHC13098IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
  • Basilea Pharmaceutica Ltd
  • BioPlx Microbiomics Pvt Ltd
  • Debiopharm International SA
  • Destiny Pharma Plc
  • Galenus Therapeutics Inc
  • Genentech USA Inc
  • HyPharm GmbH
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • Naicons Srl
  • Sichuan Saizhuo Pharmaceutical Co Ltd
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
  • afabicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BioPlx-01KS - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BioPlx-01WT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceftobiprole medocaril - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • exeporfinium chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GTX-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HY-133 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LCB-010699 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • litazolid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LTX-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAI-108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-7861 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Bacterial Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • targocil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
  • Featured News & Press Releases
  • Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  • Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
  • Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"
  • Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Genentech USA Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Lytix Biopharma AS, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021